US$ 23.08
fda approval for tirzepatide Grants a New Indication Obesity Management FDA approval for Zepbound (tirzepatide)
Description
Body weight decreased from baseline by 4.2 kg at week 16 in the tirzepatide 2.510.0 mg group and by 6.7 kg at week 24 in the 2.515.0 mg group

But what do we need to consider when using them in older age

Discontinuing GLP-1 RA leaves our patients unsupported in their battle against the inevitable weight regain that occurs as a consequence of physiological forces, such as an increase in appetite and reduction in metabolic rate

Learn more and find what fits your needs
Stopping GLP-1 medications like semaglutide before surgery requires careful timing and medical coordination
Commercial support has been prov...